Bliss GVS Pharma · NSE: BLISSGVS · BSE: 506197
Q1 FY21 results · Apr–Jun 2020
Bliss GVS Pharma reported revenue from operations of ₹129.55 crore (down 38.8% from Q1 FY20) and net profit of ₹16.65 crore (down 50.1% from Q1 FY20) for Q1 FY21 (Apr–Jun 2020), on a consolidated basis.
| Item | Q1 FY21 | Q1 FY20 | YoY | Q4 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 129.55 | 211.53 | −38.8% | 119.80 | +8.1% |
| Other income | 7.04 | 2.11 | +233.7% | 16.60 | −57.6% |
| Total income | 136.59 | 213.64 | −36.1% | 136.40 | +0.1% |
| Profit before tax | 20.40 | 47.41 | −57.0% | 13.33 | +53.0% |
| Net profit for the period | 16.65 | 33.37 | −50.1% | 5.57 | +198.9% |
| Attributable to shareholders of the company | 16.19 | 33.79 | −52.1% | 8.75 | +85.1% |
| EPS, basic (₹) | 1.57 | 3.28 | −52.1% | 0.85 | +84.7% |
| Net margin (%) | 12.9 | 15.8 | 4.7 |
| Item | Q1 FY21 | Q1 FY20 | YoY | Q4 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 114.02 | 115.16 | −1.0% | 97.97 | +16.4% |
| Other income | 6.95 | 1.79 | +287.7% | 15.24 | −54.4% |
| Total income | 120.97 | 116.95 | +3.4% | 113.21 | +6.9% |
| Profit before tax | 20.41 | 36.11 | −43.5% | 23.53 | −13.3% |
| Net profit for the period | 17.10 | 23.92 | −28.5% | 16.42 | +4.1% |
| EPS, basic (₹) | 1.66 | 2.32 | −28.4% | 1.59 | +4.4% |
| Net margin (%) | 15.0 | 20.8 | 16.8 |
Consolidated
- Filed with BSE
- 21 Aug 2020, 18:14 IST
- Board meeting
- 20 Aug 2020
- Period
- 01 Apr 2020 to 30 Jun 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 21 Aug 2020, 18:14 IST
- Board meeting
- 20 Aug 2020
- Period
- 01 Apr 2020 to 30 Jun 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE